Methods for the treatment of cancer and benign lesions by ablation
The present disclosure provides methods for the treatment of a lesion, such as a cancerous lesion, a precancerous lesion, or a benign lesion (e.g. a benign lesion on the skin) in a subject comprising administering to the subject a therapeutically effective amount of a therapy solution comprising a viscous carrier and an alcohol or hydrophobic anti-cancer agent, such that the lesion is treated. In some embodiments, the therapy solution includes an ethyl cellulose-ethanol mixture. In some embodiments, the therapy solution is administered to the lesion at a rate of from about 1 mL/hr to about 15 mL/hr.
1. A method of treating a cancerous lesion or a precancerous lesion in a subject comprising administering to the subject a therapeutically effective amount of:
a therapy solution, said therapy solution comprising a viscous carrier, wherein said viscous carrier comprises ethyl cellulose, and in which the concentration of ethyl cellulose in the therapy solution is at least 36% by weight; and
an alcohol or hydrophobic agent, such that the lesion is treated,
wherein the therapy solution is administered at a rate of from about 1 mL/hr to about 15 mL/hr.
2. The method of claim 1 , wherein upon treating, lesion size is reduced.
3. The method of claim 1 , wherein the lesion is a solid tumor.
4. The method of claim 1 , wherein the lesion is a non-capsulated tumor.
5. The method of claim 1 , wherein the lesion is a precancerous lesion.
6. The method of claim 1 , wherein the therapy solution comprises the hydrophobic agent, and the hydrophobic agent is a hydrophobic anti-cancer drug.
7. The method of claim 1 , wherein the therapy solution comprises the alcohol.
8. The method of claim 1 , wherein the lesion is a carcinoma, lymphoma, blastoma, or sarcoma.
9. The method of claim 1 , wherein the lesion is a breast cancer, prostate cancer, colon cancer, squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, gastrointestinal cancer, pancreatic cancer, liver cancer, bladder cancer, hepatoma, colorectal cancer, uterine cervical cancer, endometrial carcinoma, salivary gland carcinoma, kidney cancer, vulval cancer, pancreatic cancer, thyroid cancer, hepatic carcinoma, skin cancer, melanoma, myeloma, head and neck cancer, or Ewing sarcoma.
10. The method of claim 1 , wherein the lesion is an epithelial tumor or precancerous epithelial lesion along a lumen of the body.
11. The method of claim 1 , wherein the lesion is a cervical cancer, a head and neck cancer, an oral cancer or a precancerous lesion thereof.
12. The method of claim 1 , wherein the lesion is a cervical cancer or a cervical precancerous lesion.
13. The method as in claim 1 in which the therapy solution is administered by injection.
14. The method according to claim 1 in which the therapy solution is injected or infused directly into the lesion at one or more sites.
15. The method according to claim 1 in which about 1 mL to about 10 mL of the therapy solution is administered.
16. The method according to claim 1 , wherein the therapy solution further comprises a detectable compound.
17. The method according to claim 16 , wherein the detectable compound comprises a fluorescent compound.
18. The method according to claim 16 , wherein said method further comprises imaging the lesion to monitor distribution of the therapy solution in vivo upon administration, and/or during administration in real time.
19. The method according to claim 1 in which the concentration of ethyl cellulose in the therapy solution is at least 6% to about 10% by weight.
20. The method according to claim 1 in which the concentration of ethyl cellulose in the therapy solution is about 8% by weight.
21. The method according to claim 1 in which the concentration of ethyl cellulose in the therapy solution is about 10% by weight.